egy in non-ST-elevation acute coronary syndromes (NSTACS). Predictors of outcome with this strategy are poorly defmed. We sought to quantity the impact of baselme renal dysfunction on short and long-term mortality in patients with NSTACS treated with an very early invasive strategy. Methods: We conducted a prospective cohort study in 1400 consecutive patients with NSTACS undergoing coronary angiography and subsequent coronary stenting of the culprit lesion as the primary revascularization strategy within 24 hours of admission. Mortality in-hospital and at 3 years was stratified according to quartiles of serum creatinine and corrected creatinine clearance determined on admlssion. Time to treatment is critlcally important with thrombolytic therapy, but may be less impoltant with primary PCI.
Methods:
The CADILLAC Trial enrolled pts with AMI ~12 hrs without shock who were randomized to stenting vs PTCA +I-abciximab. Treatment time data were available in 2,002 pts.
Resulb: Median (25" and 75m percentiles) time from symptom onset to ER was 1.8 hrs (1 .O, 3.4), from ER to balloon inflation (DB time) was 2.0 hrs (1.5, 2.7) and from symptom onset to balloon Inflation @perfusion time, AT) was 4.0 hrs (2.9, 6.1). RT (hrs) was longer at US sites (4.0 vs 3.7, p=O.O02), in women (4.6 YS 3.8, p<O.OOOl). diabetics (4.6 vs 3.6, p<O.OOOl ), and pts with CFX infarcts (4.4 YS 3.9, p=O.O003). Mortality (30 day and 1 yr) was lowest with RT < 3 hrs and there was a trend for lower 1 yr re-infarction with RT < 3 hrs (Table) . After 3 hrs. further treatment delays had little impact on mortality.
DB times (cl .5 vs 1.5-2.0 vs >2.0-3.0 YS z.3.0 hrs ) had little effect on 1 yr mortality (3.4% vs 4.3% "s 4.2% "s 4.6%. p=NS).
Conclusions:
Early repelfusion (c 3 hrs) with primary PCI is associated with better 30 day and 1 yr survival and a trend toward less m-infarction at 1 yr. Delays beyond 3 hrs have little effect on survival. These data emphasize the importance of early repeltuslon and have implications regarding pt triage and the mechanism of benefit of reperfusion therapy with primary PCI. Conclusions: Although 78% of consented pts (and 90% of those undergoing PCI) were randomized in CADILLAC. pts with AMI excluded from randomization on angiographic grounds comprised an extremely high risk cohort with multiple adverse baseline features, lower procedural success, and diminished event-free wvival.
These data partly explain differences between AMI trials that randomize pts before versus after angiography. angiographic. and follow-up data were collected. According to time-to-reperfusion. patients were dwided in 4 groups: Group 1 (c 2 hours), Group 2 (2-4 hours), Group 3 (4. 6 hours), Group 4 (> 6 hours). A multivariate analysis was performed to identify independent predictors of 30-day mortality. Results. At multivariate analysis, a time-to-reperiusion > 4 hours was an independent predictors of 30.day mortality.
